Pulmonary Mucormycosis in Acute Histiocytic Leukemia Authors : Mario Stefanini , M.D. , and Salvatore Allegra , M.D. Author Info & Affiliations Published May 30, 1957 ...

The study results are reported in the manuscript “Efficacy of an oral lipid nanocrystal (LNC) formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis ...

Mucormycosis, or black fungus, has surged during the COVID-19 pandemic, particularly among those with pre-existing conditions. This severe fungal infection affects the sinuses, lungs, and brain.

Mucormycosis infections have a high mortality rate; when it spreads to the bloodstream, more than 90% of people die, says Dr. Sudhir Krishnan, pulmonary critical care physician at Cleveland Clinic.

A new lateral-flow test could one day save lives across the world through early detection of a deadly fungal disease that dramatically spiked during the COVID-19 pandemic.

In this highly lethal mouse model of mucormycosis, SCY-247 showed very promising in vivo efficacy. Orally administered SCY-247 resulted in 40% and 50% survival at 21 days post infection for the ...

Pulmonary (lung): This form primarily affects people with weakened immune systems, such as those with cancer or organ transplants. In Sri Lanka, most patients with pulmonary mucormycosis have ...

“We missed a lot of pulmonary mucormycosis during COVID,” says microbiologist Arunaloke Chakrabarti, director of the Doodhadhari Burfani Hospital and Research Institute in Haridwar, India.

The study results are reported in the manuscript “Efficacy of an oral lipid nanocrystal (LNC) formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis ...

A new lateral-flow test could one day save lives across the world through early detection of a deadly fungal disease which dramatically spiked during the COVID-19 pandemic.

BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies ...